Welcome to our dedicated page for Renovorx news (Ticker: RNXT), a resource for investors and traders seeking the latest updates and insights on Renovorx stock.
Renovorx Inc (RNXT) pioneers targeted therapeutic delivery systems designed to transform cancer treatment and vascular interventions through its proprietary Trans-Arterial Micro-Perfusion technology. This page serves as the definitive source for verified updates about the clinical-stage innovator’s progress in precision medicine.
Investors and medical professionals will find comprehensive coverage of FDA clearances, clinical trial milestones, and strategic partnerships. Track developments in RNXT’s pipeline including oncology-focused device innovations and evidence-based research validating its Renovocath™ delivery platform.
Key updates include regulatory submissions, peer-reviewed study results, manufacturing collaborations, and financial performance reports. All content is curated to support informed analysis of RNXT’s position in the competitive medical device sector while adhering to strict journalistic standards.
Bookmark this page for streamlined access to essential RNXT developments. Combine our real-time updates with Stock Titan’s financial tools to monitor this innovator in localized therapeutic delivery systems.
RenovoRx (RNXT), a life sciences company focused on targeted oncology therapies and developer of the FDA-cleared RenovoCath drug-delivery device, has scheduled its first quarter 2025 financial results conference call for May 15th, 2025, at 4:30 p.m. ET. Investors can join via phone at 1-877-407-4018 (U.S.) or 1-201-689-8471 (International), or through the webcast available on the company's investor relations website. A replay will be accessible until May 29, 2025, using pin number 13753595.
Johns Hopkins Medicine has joined RenovoRx's Phase III TIGeR-PaC clinical trial for locally advanced pancreatic cancer (LAPC) treatment. The trial will evaluate RenovoRx's innovative drug-device combination using intra-arterial gemcitabine delivery via the FDA-cleared RenovoCath device.
Key updates:
- Dr. Valerie Lee appointed as Principal Investigator at Johns Hopkins
- Dr. Michael J. Pishvaian continues as Trial Chairman
- 90 patients randomized with 50 events recorded as of March 28, 2025
- Trial requires 114 total patients and 86 events for final analysis
- Second interim analysis expected in Q2 2025
- Full enrollment targeted for completion in 2025
The study compares RenovoRx's Trans-Arterial Micro-Perfusion (TAMP) therapy platform against standard intravenous chemotherapy for LAPC treatment. Data Monitoring Committee recommendations are expected in the second half of 2025.
RenovoRx (NASDAQ: RNXT) announced increased production of its FDA-cleared RenovoCath catheter-based device at its U.S. facility in North Barrington, IL, responding to growing demand from oncologists and interventional radiologists. The company projects first-quarter 2025 revenue from RenovoCath to reach low six-figures, with expected quarter-over-quarter growth throughout the year.
The company estimates an initial total addressable market of approximately $400 million in peak annual U.S. sales for RenovoCath. Management believes this market can be captured with minimal sales force requirements, maintaining low operating expenses and targeting cash flow positive operations.
In a show of confidence, RenovoRx's management team and Board members recently purchased 143,145 shares at an average price of $0.8346 during the open trading window.
RenovoRx (RNXT) announced its participation in the LD Micro Invitational XV Conference in New York on April 10, 2025. CEO Shaun Bagai will present at 3:30 p.m. ET at the Westin Grand Central Hotel, highlighting the company's recent achievements and commercial progress.
The presentation will focus on the commercialization of their FDA-cleared RenovoCath device, including updates on new purchase orders, reorders from cancer center customers, and initial revenue generation. Additionally, Bagai will discuss the ongoing Phase III TIGeR-PaC clinical trial, which evaluates their lead drug-device combination product candidate for treating locally advanced pancreatic cancer (LAPC).
The investigational treatment combines intra-arterial delivery of gemcitabine via the RenovoCath catheter (IAG) using their proprietary Trans-Arterial Micro-Perfusion (TAMP™) therapy platform. While the RenovoCath device is FDA-cleared, the IAG combination product is still under investigation and not yet approved for commercial sale.
RenovoRx (RNXT) has reported its first commercial revenue of $43,000 in Q4 2024 from RenovoCath® device sales, marking a significant milestone. The company projects sequential revenue growth into 2025, targeting a low six-figure range for Q1. RenovoCath's initial total addressable market is estimated at $400 million in peak annual U.S. sales, with potential expansion to several billion dollars across other indications.
The company's Phase III TIGeR-PaC clinical trial has enrolled 90 patients with 50 events recorded as of March 28, 2025. A second interim analysis is expected in Q2 2025 upon reaching 52 events. The company maintains a strong financial position with $7.2 million cash as of December 31, 2024, supplemented by an additional $12.1 million raised in February 2025.
Financial results show R&D expenses of $6.0 million and SG&A expenses of $5.0 million for 2024. Net loss improved to $8.8 million compared to $10.2 million in 2023.
RenovoRx (RNXT) presented new human pharmacokinetic data at the SSO 2025 Annual Meeting, highlighting their Trans-Arterial Micro-Perfusion (TAMP) therapy platform. The study focused on their Phase III investigational drug-device combination using intra-arterial gemcitabine (IAG) with the FDA-cleared RenovoCath device.
The research, presented in abstract ePoster P379, analyzed 19 patients with locally advanced pancreatic cancer (LAPC) from six sites in the TIGeR-PaC trial. Key findings showed that localized, dual-balloon catheter-mediated IAG resulted in lower systemic levels compared to intravenous gemcitabine delivery, suggesting potential reduced chemotherapy-related side effects.
The abstract, authored by Dr. Emmanuel E. Zervos of East Carolina University and co-authored by RenovoRx's founder and CMO Dr. Ramtin Agah, demonstrates TAMP's potential as an alternative treatment for LAPC patients who struggle with traditional systemic regimens.
RenovoRx (Nasdaq: RNXT) announces that their research on the Trans-Arterial Micro-Perfusion (TAMP) therapy platform will be honored at the SIR 2025 Annual Scientific Meeting as a Journal of Vascular and Interventional Radiology Award-Winning Paper.
The peer-reviewed research demonstrates that TAMP significantly enhances drug delivery with a 100-fold increase in local tissue concentration compared to conventional intravenous delivery. The paper, titled 'Double-Balloon Catheter–Mediated Transarterial Chemotherapy Delivery in a Swine Model,' will be presented by Dr. Ramtin Agah at the conference in Nashville on April 1, 2025.
Unlike traditional systemic chemotherapy, TAMP's innovative approach uses RenovoCath®, an FDA-cleared drug-delivery device, to directly target solid tumors while potentially reducing systemic toxicity. The company is currently conducting the TIGeR-PaC Phase III clinical trial and accelerating the commercialization of RenovoCath as a standalone device through partnerships with leading oncology centers nationwide.
RenovoRx (Nasdaq: RNXT) announced a strategic fireside chat scheduled for April 3, 2025, at 12:00 p.m. ET, where CEO Shaun Bagai will provide key updates on two main fronts:
1. Commercial Progress: Discussion of RenovoCath®, their FDA-cleared drug-delivery device, including updates on new purchase orders, reorders from cancer centers, and initial revenue generation.
2. Clinical Development: Updates on the ongoing Phase III TIGeR-PaC clinical trial, which evaluates their lead drug-device combination product candidate (IAG). This candidate combines intra-arterial gemcitabine delivery via RenovoCath using their proprietary Trans-Arterial Micro-Perfusion (TAMP™) platform for treating locally advanced pancreatic cancer (LAPC).
RenovoRx (NASDAQ: RNXT) has announced the presentation of new pre-clinical data at the upcoming Society of Surgical Oncology (SSO) 2025 Annual Meeting. The abstract focuses on pharmacodynamics comparing intra-arterial versus intravenous gemcitabine in Locally Advanced Pancreatic Cancer (LAPC).
The presentation will showcase additional human pharmacokinetic (PK) and pre-clinical data supporting RenovoRx's proprietary Trans-Arterial Micro-Perfusion (TAMP™) therapy platform. This technology, utilizing the FDA-cleared RenovoCath® device, is designed to deliver targeted therapeutic treatment near tumor sites while potentially reducing systemic toxicities.
The company's ongoing Phase III TIGeR-PaC clinical trial is evaluating their investigational drug-device combination product (IAG) for LAPC treatment. RenovoRx expects to complete both patient enrollment and the second interim analysis for TIGeR-PaC in mid-2025.
RenovoRx (NASDAQ: RNXT) announced new purchase orders for its RenovoCath drug-delivery device from several National Cancer Institute-designated centers, including repeat orders from initial customers from December. The company expects to generate initial revenues this quarter, with potential revenue growth through 2025.
The FDA-cleared RenovoCath device is priced between $7,000 to $9,000 per unit, with an expected 5 to 8 annual procedures per patient. Based on these metrics and their initial target customer base, RenovoRx estimates a potential $400 million peak annual U.S. market for RenovoCath as a standalone device.
FAQ
What is the current stock price of Renovorx (RNXT)?
What is the market cap of Renovorx (RNXT)?
